ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

11024	Companies
241652	Keywords
170130	Articles
130104	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 09/23/2025 at 22:30, 11 months 25 days ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
BRIEF

published on 08/29/2025 at 08:05, 1 year ago

OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

Strategic Priorities Legal Proceedings OSE Immunotherapeutics Shareholder Activism Tedopi® And Lusvertikimab
PRESS RELEASE

published on 08/29/2025 at 08:00, 1 year ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 1 year ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab
PRESS RELEASE

published on 08/25/2025 at 07:00, 1 year ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF

published on 08/20/2025 at 18:05, 1 year ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE

published on 08/20/2025 at 18:00, 1 year ago

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet

Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
BRIEF

published on 07/02/2025 at 08:05, 1 year 2 months ago

OSE Immunotherapeutics Updates on Legal Proceedings

Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
PRESS RELEASE

published on 07/02/2025 at 08:00, 1 year 2 months ago

OSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025

Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
BRIEF

published on 06/20/2025 at 19:35, 1 year 2 months ago

OSE Immunotherapeutics secures its General Meeting

Shareholders Transparency General Assembly Legal Proceedings OSE Immunotherapeutics

Accesswire

Published on 09/18/2026 at 23:50, 1 hour 6 minutes ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 2 hours 56 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 4 hours 21 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 10 hours 26 minutes ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/18/2026 at 13:30, 11 hours 26 minutes ago

Alset AI Provides Shareholder Update, Announces Updated Investor Presentation and Appoints Mitchell Jackman as Chief Financial Officer

View all ACCESSWIRE

EQS Group

Published on 09/18/2026 at 18:45, 6 hours 11 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 6 hours 12 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 6 hours 43 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 6 hours 46 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 6 hours 49 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 6 hours 22 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 7 hours 11 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 7 hours 11 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 7 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 4 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE